AstraZeneca shares are trading higher after the company announced results from its Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease, which showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo.